In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...

A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and ...

Retrospective cohort data suggest that controlling HDL, triglycerides, and HbA1c levels may lower psoriatic arthritis risk in ...

Among patients with psoriasis who have active or recent cancer, biologic therapies show similar cancer progression or recurrence and serious infection rates compared with conventional systemic agents.

The TNF alpha inhibitors adalimumab and infliximab were associated with an increased risk for serious infection in patients with plaque psoriasis.

ASAS-PerSpA study finds Japanese patients with axial psoriatic arthritis have lower disease activity and better function than ...

Today, Takeda announced positive topline results from 2 pivotal phase 3 trials of zasocitinib (TAK-279; Takeda), demonstrating superiority over placebo across key efficacy end points in adults with ...

Researchers in China report that global incidence rates of psoriasis rose slightly from 1990 to 2021 and are projected to continue rising for both men and women through 2050. Psoriasis is a chronic ...

David Ozeri, MD, FACP, FACR, is a rheumatologist and current researcher at Sheba Medical Center in Israel. He worked at Kings County Hospital Center and treated veterans at New York Harbor Healthcare ...

Courtney is a registered nurse with over 13 years of experience in the clinical setting, helping individuals navigate their way through their healthcare journeys. She has been in the frontlines ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...